Effect Of Creatine Monohydrate On Clinical Progression In Patients With Parkinson Disease: A Randomized Clinical Trial
Notes for this study:
|Number of Subjects
||Obese, Overweight, Average
Participants with early-stage Parkinson’s disease (within 5 years of diagnosis) who also underwent dopaminergic therapy were randomized to receive a placebo or 5 g of creatine twice a day (10 g/day) for a minimum of 5 years. At a preplanned checkpoint, however, the trial was terminated early for futility, as no difference in clinical function (using 5 different scales) was observed between the placebo and creatine groups.